Chemokine (C-C motif) ligand 2 (CCL2), initially identified as monocyte chemoattractant protein-1 (MCP-1), recruits immune cells to the central nervous system (CNS) during autoimmune inflammation. CCL2 can be expressed by multiple cell types, but which cells are responsible for CCL2 function during acute and chronic phases of autoimmune disease is not known. We determined the role of CCL2 in astrocytes in vivo during experimental autoimmune encephalomyelitis (EAE) by using Cre-loxP gene deletion. Mice with a conditional gene deletion of CCL2 from astrocytes had less severe EAE late in disease while having a similar incidence and severity of disease at onset as compared to wild type (WT) control littermates. EAE mice devoid of CCL2 in astrocytes had less macrophage and T cell inflammation in the white matter of the spinal cord and less diffuse activation of astrocytes and microglia in both white and gray matter as well as less axonal loss and demyelination, compared to WT littermates. These findings demonstrate that CCL2 in astrocytes plays an important role in the continued recruitment of immune cells and activation of glial cells in the CNS during chronic EAE, thereby suggesting a novel cell specific target for neuroprotective treatments of chronic neuroinflammatory diseases.
Introduction
Inflammation characterizes many disorders of the central nervous system (CNS), including neurodegenerative, traumatic and autoimmune disorders. In neurodegenerative and traumatic disorders, CNS inflammation is locally restricted and tends to resolve over time (Bush et al., 1999; Schnell et al., 1999; Donnelly and Popovich, 2008) . In contrast, in autoimmune disorders, CNS inflammation is widespread and continuous or recurring (Raine et al., 1980; Lucchinetti et al., 2000; McFarland and Martin, 2007) . Understanding which molecule on which cell regulates the continuous influx of inflammatory cells into the CNS during autoimmune disease is central to the development of treatment strategies aiming to block continuous inflammation.
Multiple sclerosis (MS) is an autoimmune disease of the CNS characterized by continuous inflammation, demyelination and axonal loss. Current treatment strategies are only partially effective at controlling peripheral immune responses, reduce relapse rates and delay, but do not halt, permanent disability accumulation and ongoing neurodegeneration (Hauser et al., 2013) . Thus, there is a need to develop treatments that target molecules on CNS cells to achieve more direct neuroprotection. Experimental autoimmune encephalomyelitis (EAE) is the most widely used animal model for MS. It has been used for decades to study peripheral immune responses and was central to the development of many currently approved treatments in MS (Yednock et al., 1992; Yu et al., 1996; Aharoni et al., 1997; Webb et al., 2004; Prinz et al., 2008) . More recently the chronic progressive EAE model in C57BL/6 mice has been used to study neurodegenerative aspects of the disease as a means toward finding a neuroprotective treatment (Bannerman et al., 2005; Rasmussen et al., 2007; Aharoni et al., 2008; Xu et al., 2008; MacKenzie-Graham et al., 2009; Ziehn et al., 2010; Rasmussen et al., 2011; MacKenzie-Graham et al., 2012; Ziehn et al., 2012; Mori et al., 2013) .
Astrocytes are intimately associated with and signal to blood vessels (Iadecola and Nedergaard, 2007) and are recognized as playing important roles in regulating leukocyte trafficking and inflammation in the CNS. They produce a wide variety of pro-inflammatory chemokines and cytokines, as well as reactive oxygen species (ROS) in vitro, consistent with a pro-inflammatory role (Dong and Benveniste, 2001; Chen and Swanson, 2003; Farina et al., 2007; Nair et al., 2008) . Conversely, astrocytes also produce anti-inflammatory cytokines and ROS scavengers, thereby suggesting a role in mitigating inflammation Journal of Neuroimmunology 274 (2014) 53-61 
